GIST & Other Sarcomas with Actionable Targets

(P 095) A COLLABORATIVE MULTIDISCIPLINARY APPROACH MAY LEAD TO ENHANCED CLINICAL OUTCOMES AND QUALITY OF CARE FOR PATIENTS WITH DIFFUSE TGCT

(P 096) AN OPEN-LABEL, PHASE 2 EFFICACY STUDY OF TEMOZOLOMIDE IN ADVANCED SUCCINATE DEHYDROGENASE-MUTANT/DEFICIENT GASTROINTESTINAL STROMAL TUMOR

(P 097) COMBINATION THERAPY OF TYROSINE KINASE INHIBITORS WITH RIPRETINIB AS THERAPEUTIC EXPLORATION FOR REFRACTORY GASTROINTESTINAL STROMAL TUMORS AFTER PROGRESSION FROM STANDARD THERAPY: A CASE REPORT

(P 098) COMBINATION THERAPY WITH IMATINIB AND PAC-1 INDUCES TREATMENT SYNERGISM IN GASTROINTESTINAL STROMAL TUMORS

(P 100) COPY NUMBER ALTERATIONS IN CDKN2A AND CDKN2B ARE ASSOCIATED WITH WORSENED OVERALL SURVIVAL IN PATIENTS WITH GIST

(P 101) CYTOREDUCTIVE SURGERY FOR METASTATIC GASTROINTESTINAL STROMAL TUMORS TREATED WITH RIPRETINIB: A SINGLE-CENTER ANALYSIS.

(P 102) EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION

(P 103) GIST PATIENT AND TUMOR CHARACTERISTICS IN REFERENCE CENTERS AND NON-REFERENCE CENTERS: DATA FROM A NATIONWIDE REGISTRY

(P 104) INFANTILE EXTRARENAL SPINDLE CELL MESENCHYMAL NEOPLASMS WITH TARGETABLE EGFR KINASE DOMAIN DUPLICATIONS

(P 106) LAPAROSCOPY IN GASTRIC GIST: RETROSPECTIVE PRE-POST COMPARISON ANALYSIS OF SHORT TERM OUTCOMES ON A CONSECUTIVE SERIES OF 95 CASES FROM A TERTIARY REFERRAL CENTRE

(P 107) LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS

(P 108) NILOTINIB REVISITED: SALVAGE USE IN PATIENTS WITH SEVERE IMATINIB-TOXICITY

(P 109) NOVEL CANDIDATE BIOMARKERS FOR FLUORESCENCE IMAGE-GUIDED SURGERY IN GASTROINTESTINAL STROMAL TUMORS

(P 110) PHASE I RESULTS FROM A MULTI-PHASE COMPREHENSIVE GENOMIC SEQUENCING TUMOR STUDY IN GASTROINTESTINAL STROMAL TUMOR PATIENTS

(P 111) PLASMA CONCENTRATION MONITORING AND PERSONALIZED DESENSITIZATION THERAPY IN PATIENTS OF GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB-ASSOCIATED SKIN RASH

(P 112) PREVALENCE AND PROGNOSTIC VALUE OF TARGETABLE RECEPTORS IN EXTRA-UTERINE LEIOMYOSARCOMA

(P 113) PROGNOSTIC AND/OR PREDICTIVE VALUE OF EXON 11 MUTATIONS IN TUMOR RESPONSE TO IMATINIB IN METASTATIC GASTROINTESTINAL STROMAL TUMOR :RETROSPECTIVE ANALYSIS OF A MULTICENTRIC NATIONAL REGISTRY

(P 114) PROGNOSTIC IMPACT OF CIRCULATING TUMOR DNA DETECTION IN FIRST-LINE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR

(P 116) SAFETY AND EFFICACY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: LONG-TERM PHASE 1 UPDATE

(P 117) SHOULD REGORAFENIB BE PRESCRIBED AS A CONTINUOUS SCHEDULE AT LEAST IN GASTROINTESTINAL STROMAL TUMORS (GIST)?

(P 118) SOMATOSTATIN RECEPTOR TYPE 2 EXPRESSION IN SARCOMA

(P 119) SURGICAL MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOURS SARCOMATOSIS (GISTOSIS). A RETROSPECTIVE MULTI-INSTITUTIONAL STUDY

(P 120) THE DIAGNOSTIC AND PROGNOSTIC VALUE OF PLASMA SMALL EXTRACELLULAR VESICLES PHENOTYPE IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOUR

(P 121) USING IN VITRO MODELS TO PREDICT IMATINIB RESPONSES IN PDGFRA-MUTANT GASTROINTESTINAL STROMAL TUMOR